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Abstract
Background: Antigen presenting cells (APCs) sample the extra cellular space and present
peptides from here to T helper cells, which can be activated if the peptides are of foreign origin.
The peptides are presented on the surface of the cells in complex with major histocompatibility
class II (MHC II) molecules. Identification of peptides that bind MHC II molecules is thus a key step
in rational vaccine design and developing methods for accurate prediction of the peptide:MHC
interactions play a central role in epitope discovery. The MHC class II binding groove is open at
both ends making the correct alignment of a peptide in the binding groove a crucial part of
identifying the core of an MHC class II binding motif. Here, we present a novel stabilization matrix
alignment method, SMM-align, that allows for direct prediction of peptide:MHC binding affinities.
The predictive performance of the method is validated on a large MHC class II benchmark data set
covering 14 HLA-DR (human MHC) and three mouse H2-IA alleles.
Results: The predictive performance of the SMM-align method was demonstrated to be superior
to that of the Gibbs sampler, TEPITOPE, SVRMHC, and MHCpred methods. Cross validation
between peptide data set obtained from different sources demonstrated that direct incorporation
of peptide length potentially results in over-fitting of the binding prediction method. Focusing on
amino terminal peptide flanking residues (PFR), we demonstrate a consistent gain in predictive
performance by favoring binding registers with a minimum PFR length of two amino acids.
Visualizing the binding motif as obtained by the SMM-align and TEPITOPE methods highlights a
series of fundamental discrepancies between the two predicted motifs. For the DRB1*1302 allele
for instance, the TEPITOPE method favors basic amino acids at most anchor positions, whereas the
SMM-align method identifies a preference for hydrophobic or neutral amino acids at the anchors.
Conclusion: The SMM-align method was shown to outperform other state of the art MHC class
II prediction methods. The method predicts quantitative peptide:MHC binding affinity values,
making it ideally suited for rational epitope discovery. The method has been trained and evaluated
on the, to our knowledge, largest benchmark data set publicly available and covers the nine HLA-
DR supertypes suggested as well as three mouse H2-IA allele. Both the peptide benchmark data
set, and SMM-align prediction method (NetMHCII) are made publicly available.
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Background
Major histocompatibility complex molecules (MHCs)
play an essential role in the host pathogen interactions
determining the onset of a host immune response. One
arm of the cellular immune system is guided by the MHC
class I complexes that present peptides derived from intra
cellular proteins to cytotoxic T cell circulating in the blood
periphery. The MHC class II complexes guide the other
arm of the cellular immune system. These complexes
present peptides derived from endocytosed proteins to
CD4+ helper T lymphocytes (HTLs) to stimulate cellular
and humoral immunity against the pathogenic microor-
ganism.
Predicting the peptides that bind to MHC class II mole-
cules can effectively reduce the number of experiments
required for identifying helper T cell epitopes and play an
important role in rational vaccine design. Large efforts
have been invested in deriving such prediction methods.
In general terms, the different methods can be classified in
two groups. One group being quantitative matrices esti-
mated from experimentally derived position specific
binding profiles [1-3], and the other group comprising
data driven bioinformatical motif search methods. The
number of different bioinformatical methods proposed to
predict MHC class II binding is large and growing includ-
ing Gibbs samplers [4], Ant colony [5], Artificial neural
networks [6], Support vector machines [7,8], hidden
Markov models [9], and other motif search algorithms
[10-12]. However, most of these methods have been
trained and evaluated on very limited data sets covering
only a single or a few different MHC class II alleles. Fur-
ther the majority of the methods are trained on MHC lig-
and data (peptides eluted from MHC complexes present
on the cell surface). This type of qualitative prediction
methods are well suited to classify data in to binders and
non-binders, but they do not allow a direct prediction of
the peptide:MHC binding strength.
Recently, a large set of quantitative MHC class II peptide-
binding data has been made publicly available on the
IEDB databases [13]. The data set comprises peptide data
with IC50 binding affinities for more than 14 HLA
(human MHC) and several mouse MHC class II alleles.
Here, we present a novel method, SMM-align, for quanti-
tative MHC class II binding predictions. The method is an
extension of the stabilization matrix method proposed by
Peters et al. [14]. The SMM-align method seeks to identify
a weight matrix that optimally reproduces the measured
IC50 values for each peptide in the training set.
The method allows for identification the MHC class II
binding motif in terms of a position specific weight
matrix. The output of the SMM-align method is IC50
binding affinity values, enabling direct readout of the pep-
tide:MHC binding affinity.
To our knowledge, only three other methods are publicly
available for quantitative MHC class II prediction, namely
the ARB [12], SVRMHC [7] and MHCpred [15] methods.
Other methods such as SVMHC [16] and Propred [17] are
implementations of the TEPITOPE method [3], and pro-
vide prediction scores that are not in any direct way pro-
portional to the peptide binding affinity. Both the
SVRMHC and MHCpred methods are trained on relatively
small sets of quantitative peptide binding data contained
within the AntiJen database [18] and could probably
improve if retrained on the data used here. The SVRMHC
method covers six, and MHCpred three MHC class II alle-
les, respectively. The ARB method is trained on quantita-
tive peptide binding data available within the IEDB
database [13]. The TEPITOPE is an experimentally derived
virtual matrix based prediction method that covers 50 dif-
ferent HLA-DR alleles, and relies on the approximation
that the peptide binding specificity can be determined
solely from alignment of MHC pockets amino acids [3].
In this work, we design a large-scale benchmark calcula-
tion covering 14 HLA-DR and three mouse H2-IA alleles.
We compare the predictive performance of five methods
in terms of their ability to predict binding affinity of more
than 4600 peptides. The methods included in the bench-
mark are; SMM-align, Gibbs sampler [4], SVRMHC [7],
MHCpred [15], ARB [12] and TEPITOPE [3].
Results
The SMM-align method was applied to derive a position
specific scoring matrix for prediction of MHC-II binding
affinities for each of the 14 HLA-DR and three H2-IA alle-
les in the benchmark dataset. The predictive performance
of the method was estimated using five-fold cross-valida-
tion.
Cross-validated predictive performance
The predictive performance of the SMM-align method is
compared to that of the Gibbs sampler, TEPITOPE,
SVRMHC, MHCpred, and ARB methods. The SMM-align,
Gibbs sampler, and ARB methods cover all 14 alleles.
TEPITOPE covers 11, SVRMHC five, and MHCpred only
three of the 14 alleles. The predictive performance of the
different methods was measured in terms of the area
under the ROC curve (AUC) [19], the Pearson correlation
[20], and the Spearman's rank correlation [20]. Since the
TEPITOPE method does not produce prediction values
that are linearly related to the log-transformed IC50 bind-
ing affinities, the use of the Pearson correlation coefficient
would be an inappropriate measure for the prediction
accuracy for this method. Hence, we for this method only
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evaluate the predictive performance using the other two
measures.
Table 1 gives a summary of the HLA-DR benchmark calcu-
lation results.
The table demonstrates the predictive power of the SMM-
align method as compared to that of the other methods.
Note that caution should be taking when evaluating the
predictive performance of the ARB method. This method
has been trained on data from the IEDB database, and
thus very likely has been trained on data included in the
benchmark evaluation set. The Gibbs sampler has relative
poor performance compared to the SMM-align method.
There are many possible reasons for this low performance.
Most importantly, the Gibbs sampler method is trained
on qualitative data only. Before applying the Gibbs sam-
pler method, the data are classified into binders and non-
binders, and only the set of binders are included when
estimating the binding motif weight matrix. The SMM-
align method, on the other hand, includes both binding
and non-binding data when estimating the motif weight
matrix.
The details of the benchmark calculation as evaluated in
terms of the AUC performance measure are shown in
Table 2 (evaluation in terms of the Pearson's and Spear-
man's rank correlations are shown in Supplementary
materials table 1 [see Additional file 1]).
The SMM-align, ARB and TEPITOPE methods all have
similar predictive performances. Comparing to the other
methods the SMM-align method has the highest predic-
tive performance, followed by the Gibbs sampler and
SVRMHC methods. The MHCpred method performs the
poorest. The direct relation between the SMM-align pre-
diction scores and the log-transformed IC50 binding
affinity is confirmed by fact that a least square linear fit to
the log-transformed binding data as a function of the
SMM-align prediction values has a slope close to unity
(data not shown).
Table 1: Summary of the HLA-DR benchmark results.
AUC
Allele SMM Gibbs TEPITOPE SVRMHC MHCpred ARB SMM-PRF NetMHCII N
A 0.730 0.697 0.758 0.749 0.756 14
B 0.740 0.705 0.736 0.762 0.748 0.750 11
C 0.710 0.690 0.714 0.688 0.719 0.719 0.722 5
D 0.737 0.710 0.723 0.606 0.717 0.749 0.754 3
Pearson correlation
Allele SMM Gibbs TEPITOPE SVRMHC MHCpred ARB SMM-PRF NetMHCII N
A 0.420 0.368 0.464 0.436 0.448 14
C 0.408 0.369 0.157 0.431 0.428 0.435 5
D 0.458 0.384 0.218 0.425 0.480 0.487 3
Spearman's rank correlation
Allele SMM Gibbs TEPITOPE SVRHMM MHCpred ARB SMM-PRF NetMHCII N
A 0.430 0.372 0.464 0.445 0.453 14
B 0.443 0.378 0.428 0.479 0.458 0.463 11
C 0.398 0.353 0.430 0.377 0.424 0.422 0.427 5
D 0.450 0.365 0.434 0.210 0.407 0.474 0.481 3
The predictive performance is shown in terms of the average area under the ROC curve (upper panel), the average Pearson's correlation (middle 
panel), and the average Spearman's rank correlation (lower panel) for the SMM (SMM-align), Gibbs sampler [4], TEPITOPE [3], SVRMHC [7], 
MHCpred [15], and ARB [12] methods, respectively. The SMM-PRF method refers to the extended SMM align method including penalties for longer 
peptides and short amino terminal peptide flanking residues, and the NetMHCII method refers to the extended SMM align method including direct 
encoding of peptide flanking residues and penalties for longer peptides and short amino terminal peptide flanking residues. The last column gives the 
number of alleles included in each average. In A is shown the average performance for all 14 HLA-DR alleles, in B the average performance for the 
subset of 11 alleles covered by the TEPITOPE method, in C the average performance for the five alleles covered by the SVRMHC method, and in D 
the average performance for the three alleles covered by the MHCpred method. For each allele, the performance of the SMM-align, Gibbs sampler, 
and NetMHCII methods was estimated using five-fold cross-validation as described in Methods.
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Incorporating the peptide length in prediction of 
peptide:MHC class II binding
Chang et al. [11] recently proposed a strategy for incorpo-
rating of peptide length into prediction of peptide-MHC
class II binding, and demonstrated that at least for some
alleles the approach lead to significant improvements in
prediction accuracy.
Here, we evaluate the peptide length-based approach on
two data sets covering the three alleles included in the
work by Chang et al. [11]. The data are taken from two
sources. AntiJen: Data from the AntiJen database as down-
loaded from the supplementary data in Chang et al., and
IEDB: Data from the IEDB database [13]. For each allele
in the two data sets, we train the SMM-align method in
three distinct manners; a) using no peptide length infor-
mation, b) including a peptide length affinity baseline
estimated from the training data as described by Chang et
al., and c) including a peptide length affinity baseline esti-
mated from the data in the alternative data set, i.e., using
the DRB1*0101 AntiJen data set to estimate the baseline
correction for the training of the IEDB DRB1*0101 data
and vise versa. The result of the benchmark calculation is
shown in Table 3.
Focusing on the first three rows in the table comparing,
the predictive performance of the SMM method is seen to
compare favorably to that of both ISC-PLS, and
TEPITOPE. The average predictive performance in terms
of AUC for the ISC-PLC, TEPITOPE, and SMM methods
on the three alleles in the AntiJen data sets is 0.692, 0.692,
and 0.738, respectively. Further, the table shows that the
performance gain proposed the Chang et al. for the Anti-
Jen DRB1*0101, and DRB1*1501 allele data sets is recov-
ered in our implementation (see SMM-regr). However, it
is striking to observe that the alternative baseline correc-
tion consistently for all alleles leads to a dramatic drop in
predictive performance (see SMM-regr-alter). This sug-
gests that the baseline subtraction, rather than being alle-
les specific, is highly data set dependent and that the
performance gain observed including an affinity baseline
correction does not necessarily reflect a genuine feature of
MHC class II binding predictions, but may arise as a result
of over-fitting the method to a length distribution and
binding profile of a particular data set.
We observed a large discrepancy between the affinity-
length profiles for the peptide data in the AntiJen, IEDB
and SYFPEITHI databases (details of the calculation are
shown in Supplementary materials, Figure 1 [see Addi-
tional file 2]). The short peptides (length < 15 amino
acids) in the IEDB data set, seems to follow an affinity
profile in agreement with the observed length profile for
natural MHC-II ligands in the SYFPEITHI database. This is
in contrast to what was observed for the peptides the Ant-
iJen data set. For longer peptides, both the AntiJen and
Table 2: Details of the benchmark calculation covering the 14 HLA-DR alleles.
AUC
Allele SMM Gibbs TEPITOP
E
SVRMHC MHCpred ARB SMM -PRF NetMHCII N
1*0101 0.702 0.676 0.647 0.623 0.565 0.666 0.716 0.716 1203
1*0301 0.779 0.722 0.734 0.799 0.770 0.765 474
1*0401 0.741 0.759 0.754 0.739 0.606 0.737 0.756 0.758 457
1*0404 0.798 0.743 0.829 0.788 0.808 0.785 168
1*0405 0.727 0.724 0.790 0.701 0.724 0.733 0.735 171
1*0701 0.768 0.695 0.768 0.647 0.749 0.774 0.787 310
1*0802 0.724 0.721 0.769 0.803 0.740 0.756 174
1*0901 0.726 0.734 0.711 0.759 0.775 117
1*1101 0.715 0.715 0.710 0.727 0.720 0.734 359
1*1302 0.810 0.716 0.720 0.917 0.819 0.818 179
1*1501 0.715 0.672 0.726 0.730 0.792 0.733 0.736 365
3*0101 0.620 0.512 0.717 0.771 0.815 102
4*0101 0.730 0.742 0.800 0.729 0.736 181
5*0101 0.664 0.618 0.653 0.649 0.677 0.655 0.664 343
The predictive performance is shown in terms of the area under the ROC curve (AUC) for the SMM-align, Gibbs sampler [4], TEPITOPE [3], 
SVRMHC [7], MHCpred [15], and ARB methods, respectively. The SMM-PRF method refers to the extended SMM align method including penalties 
for long peptides and short amino terminal peptide flanking residues, and the NetMHCII method refers to the final extended SMM align method 
including direct encoding of peptide flanking residues and penalties for longer peptides and short amino terminal peptide flanking residues. The first 
column gives the allele names as 1*0101 for DRB1*0101 etc The last column gives the number of peptide data included for each allele. For each 
allele, the performance of the SMM-align, Gibbs sampler, and NetMHCII methods was estimated using five-fold cross-validation as described in the 
text. The details of the benchmark calculation as measured in terms of the Pearson's and Spearman's rank correlation are shown in Supplementary 
materials table 1 [see Additional file 1].
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IEDB data sets followed a similar affinity profile that devi-
ated strongly from the length profile of natural MHC-II
ligands. The large discrepancy between the affinity-length
profiles for the two databases provides a possible explana-
tion as to why the alternative baseline correction gives so
poor predictive performance. While the AntiJen data sets
tend to have high binding affinities for short peptides, the
opposite is the case for the IEDB data sets, and applying
an AntiJen derived baseline correction to an IEDB data set
thus could give no improvement to the prediction results.
Including peptide flanking residues
Looking at differences in the length distribution of the
amino terminal peptide flanking residues (PFR) as identi-
fied by the SMM alignment method, suggest a feature
common to both the AntiJen and IEDB data that separates
binding from non-binding peptides.
In Figure 1, the length distribution of the amino terminal
PFRs is shown for the combined set of binding and non-
binding peptides in the AntiJen, and IEDB data sets,
respectively. In the figure, a PFR length of zero indicates
that the MHC-II binding core starts at the amino terminal
of the peptide leaving a flanking region of zero amino
acids. From the figure, it is apparent that a significantly
larger fraction of the non-binding peptides have amino
terminal PFRs shorter than 2 amino acids (p < 0.001, Fish-
ers exact test), suggesting that amino terminal PFRs do
play an important role in stabilizing the peptide:MHC
complex. A similar picture is not observed at the C termi-
nal (data not shown).
The requirement for presence of amino terminal flanking
amino acids in combination with the observation that the
SMM algorithm tends to over-predict the binding affinity
for longer peptides (data not shown), suggests a simple
scheme suitable for modifying the SMM predictions
where S is the original prediction score from the SMM
method, and p is a parameter determining the penalty for
short PFRs and longer peptides. In a small cross validation
S’ =
− <
− >
S p, if amino PFR length 2
S p, if peptide length 15
S, otherwise
⎧
⎨
⎪⎪
⎩
⎪⎪
Length distribution of amino terminal PFRs for MHC-II bind-ing and non- inding peptidesFi ure 1
Length distribution of amino terminal PFRs for MHC-II bind-
ing and non-binding peptides. All peptide data for the three 
alleles in the AntiJen and IEDB data sets are included in the 
figure. Binding peptides have an affinity stronger than 500 nM. 
The PFR is defined as the residues flanking the peptide-bind-
ing core as determined by the SMM-align method.
Table 3: Predictive performance in terms of the area under the ROC curve (AUC) of the different methods evaluated on six data sets.
AntiJen IEDB
DRB1*0101 DRB1*0401 DRB1*1501 DRB1*0101 DRB1*0401 DRB1*1501
ISC-PLC 0.709 0.757 0.609
SMM-align 0.718 0.806 0.691 0.702 0.741 0.715
TEPITOPE 0.667 0.744 0.665 0.647 0.754 0.726
Chang 0.770 0.757 0.677
SMM-regr 0.807 0.819 0.741 0.744 0.750 0.718
SMM-regr-alter 0.616 0.785 0.669 0.645 0.721 0.712
SMM-PFR 0.742 0.814 0.726 0.716 0.756 0.733
The methods are; ISC-PLS [15], SMM-align, TEPITOPE, Chang [11], SMM-regr (SMM with peptide length regression correction from training data 
set), SMM-regr-alter (SMM with peptide length regression correction from alternative AntiJen/IEDB dataset), and SMM-PFR (The SMM-PRF method 
refers to the extended SMM align method including penalties for long peptides and short amino terminal peptide flanking residues). The data sets 
consist of peptides binding data from two sources (IEDB and AntiJen) covering three HLA-DR alleles (1*0101, 1*0401, and 1*1501). Performance 
value for the ISC-PLS and Chang methods, are taken from Chang et al. [11]. These values are only available for the AntiJen data set.
BMC Bioinformatics 2007, 8:238 http://www.biomedcentral.com/1471-2105/8/238
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experiment, an optimal value for p was determined to be
equal to 0.1.
The predictive performance using this ad-hoc modifica-
tion scheme is shown in Table 1 through Table 3 as SMM-
PFR. From the table, it is apparent that the modification
improves the predictive performance for all alleles in both
data sets. The average performance in terms of AUC for
the SMM-align method on the six alleles common to the
IEDB and AntiJen data sets is 0.729. Using the proposed
modification scheme this number is increased to 0.748.
For the alleles in the IEDB data set, the average predictive
performance of the SMM-align method is 0.730. This
value is increased to 0.749 using the PFR modification
scheme. In total the PRF modification scheme improved
the predictive performance for 15 of the 17 (14 IEDB and
3 AntiJen) data sets, making the improvement highly sta-
tistical significant (p = 0.001, Fishers exact test).
An attempt to directly encode the amino acids composi-
tion of the PFR's as input to the SMM-align method gave
further improvements to the prediction accuracy. Here,
the SMM weight matrix was extended to a length of 11 to
incorporate the effect of PFR's. PFR's were encoded to the
SMM-align method as the average Blosum62 score [21]
over a maximum length of three amino acids. The average
predicted performance in terms of the AUC using this PFR
encoding scheme in combination with the penalty for
longer peptides and short amino terminal peptide flank-
ing residues was 0.756 for the alleles in the IEDB data set,
and 0.750 for the six alleles in the combined AntiJen and
IEDB data set. The performance excluding PRF sequence
encoding and including only the penalty for longer pep-
tides and short amino terminal peptide flanking residues
was 0.749, and 0.748, respectively, for the two datasets.
The gain in predictive performance is minor. However,
the performance is consistently increased for all three alle-
les in AntiJen data set, and is increased for 11 of the alleles
in the IEDB data set, making the improvement highly sta-
tistical significant (p = 0.001, Fishers exact test) suggesting
that amino acid composition of the PFRs does play some
role in stabilizing the peptide:MHC complex.
Mouse H2-IA alleles
Next, the SMM-align method was applied to derive a
method for prediction of MHC-II binding affinities for set
of three mouse H2-IA alleles in the benchmark dataset.
The predictive performance of the method was estimated
using five-fold cross-validation. The methods SMM-align,
ARB [12] and PredBalbc [22] were included in the bench-
mark. Table 4 gives the results in terms of the AUC predic-
tive performance of the benchmark calculation.
The table demonstrates the predictive power of the SMM-
align method, as the performance is higher than or com-
parable to that of the ARB method. Note that caution
should also here be taking when evaluating the predictive
performance of the ARB method. This method has been
trained on data from the IEDB database, and thus very
likely has been trained on data included in the evaluation
set. The PredBalbc method seems to perform significantly
worse that the other two methods. Noteworthy is the lim-
ited gain in predictive performance of the SMM align
method when including peptide flanking residues and
penalty for long peptides and short amino terminal pep-
tide flanking residues. Here, the H2-IAb allele shows a
drop in predictive performance when including PRFs.
However, the H2-IAb allele is trained on very limited
amount of peptide data, and one could speculate that PRF
might improve the predictive performance also for this
allele, as more peptide training data becomes available.
The final NetMHCII prediction method
The final MHC class II prediction method covers 14 HLA-
DR and three H2-IA alleles. For each allele, the method is
trained in a five-fold cross-validated manner as described
in Methods using multiple sequence encoding schemes,
Gibbs sampler derived position specific weight matrices,
direct encoding of PRFs and penalties for longer peptides
and short amino terminal peptide flanking residues. We
denote the final method NetMHCII.
Visualization of the peptide binding motifs
The difference in predictive performance between the
SMM-align and TEPITOPE method is striking for several
Table 4: Summary of the mouse H2-IA benchmark.
AUC
Allele SMM NetMHCII ARB PredBalbc N
H-2-IAb 0.913 0.908 0.662 76
H-2-IAd 0.819 0.818 0.819 0.659 342
H-2-IAs 0.877 0.898 126
The predictive performance is shown in terms of the average area under the ROC curve. The methods included in the benchmark are SMM (SMM-
align), NetMHCII (the extended SMM-align method including direct encoding of peptide flanking residues and penalties for longer peptides and short 
amino terminal peptide flanking residues), ARB [12], and PredBalbc [22]. The performance of the SMM and NetMHCII methods was estimated using 
five-fold cross-validation as described in Methods.
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alleles. The binding motifs can be visualized in a highly
condensed manner using sequence logos [23]. Figure 2
shows such Kullback-Leibler logos [24] for the binding
motifs determined by the SMM-align, Gibbs sampler, and
TEPITOPE methods, respectively, for the alleles
DRB1*0101, and DRB1*1302. The logos are determined
from the top 1% of 10.000 random natural peptides
selected from the SWISS-PROT database [25]. For the
DRB1*0101 allele, the logos show a clear agreement
between all three methods, with three major anchors at
positions 1, 4 and 6. However, for the DRB1*1302 allele,
the logos are in strong disagreement both with regard to
the location of and the preferred amino acids at the
anchor positions. The TEPITOPE method identifies the
position 1 and 4 as anchors, with all anchors except P1
preferring basic amino acids. The SMM-align method, on
the other hand, identifies positions 1 and 3 as primary
anchors, all with a strong preference for neural or hydro-
phobic or neutral amino acids.
Discussion
We have developed an integrated alignment and motif
identification algorithm, SMM-align. The method is a
hybrid between the SMM method proposed by Peters et
al. [14], and the Gibbs sampler method [4]. The method
is trained on quantitative MHC:peptide binding data,
allowing for a direct prediction of MHC:peptide binding
affinities. The peptide data is encoded to the SMM-align
method using several sequence schemes including sparse,
Blosum and position specific weight matrix encoding. The
Kullback-Leibler logo visualizations of peptide binding motifsFigure 2
Kullback-Leibler logo visualizations of peptide binding motifs. The upper panel depicts the motif for the DRB1*0101 allele, and 
the lower panel the motif for the DRB1*1302 alleles. From left the different columns show the motif estimated by the SMM 
(NetMHCII), Gibbs sampler, and TEPITOPE methods, respectively. The height of a column in the logo is proportional to the rel-
ative information content in the sequence motif, and the letter height is proportional to the amino acid frequency [23]
BMC Bioinformatics 2007, 8:238 http://www.biomedcentral.com/1471-2105/8/238
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binding prediction is determined as the ensemble average
over the predictions obtained from the different encoding
schemes. The search for the optimal SMM-align solution
is performed using a Metropolis Monte Carlo (MC) search
[26]. To allow for an effective sampling of the potentially
large number of local minima in the weight space, an
ensemble average of suboptimal MC solution was
included in the SMM-align method. Finally for the human
HLA-DR alleles, prior knowledge of the preferred amino
acids at the P1 position in the binding motif was imple-
mented to guide the MC search. The final method is
termed NetMHCII and covers 14 HLA-DR and three
mouse H2-IA alleles.
The large-scale MHC class II peptide binding benchmark
covering 14 HLA-DR and three mouse H2-IA alleles ena-
bled an evaluation of the predictive performance of a set
of different publicly available prediction methods includ-
ing the Gibbs sampler, TEPITOPE, SVRMHC, MHCpred,
and ARB methods. For each allele, the peptide binding
data were split into five groups each with minimal
sequence overlap and thus ideally suited for cross-vali-
dated method validation. The benchmark calculation
demonstrated that for the HLA-DR alleles the NetMHCII
method outperforms most of the other methods. Only the
ARB method had a comparable performance. However, a
direct comparison to the predictive performance of the
ARB method is difficult since the ARB method most likely
is trained on the data included in the evaluation sets. The
MHCpred method was shown to have the poorest per-
formance. A general tendency was observed for small
training data set where the TEPITOPE and NetMHCII pre-
diction methods achieve comparable predictive perform-
ances, underlining the need for large data sets in order to
generate accurate MHC class II prediction methods.
Incorporation of peptide length in to MHC class II bind-
ing prediction algorithms as suggested by Chang et al.
[11] was demonstrated to result in a potential strong over-
fitting of the predictive performance. In a cross-validation
experiment using affinity data from both the AntiJen and
IEDB databases, the two data sets were shown to have
highly different peptide length binding profiles, suggest-
ing that the performance gain reported by Chang et al. not
necessarily reflects a genuine feature of MHC class II bind-
ing predictions, but could arise as a result of over-fitting
the method to a length distribution and binding profile of
a particular data set. One can speculate why the two data
sets have so different affinity-length profiles. A possible
reason could be that a large fraction (13%) of the peptides
in the AntiJen data have an unnatural amino acid compo-
sition (more than 70% alanin for instance). The fraction
of unnatural peptides is less than 1% for the IEDB data set.
The similarity in profile between the IEDB and SYFEITHI
data sets suggests that short peptides with length less than
13–14 amino acids do indeed bind poorly to MHC class
II molecules. Both the IEDB and AntiJen affinity profiles
show that the likelihood of binding has limited depend-
ence on peptide length for longer peptides. This is in large
disagreement with the length profile for natural MHC-II
ligands, where the likelihood of observing a peptide of a
given length decreases rapidly as the peptide length passes
16 amino acids. However, here it is important to stress the
different nature of the three data sets. Both the IEDB and
AntiJen data sets contain quantitative data on in-vitro
binding of peptides to MHC-II molecules. The SYFPEITHI
data set, on the other hand, reflects the length of peptides
that are naturally presented through the class II antigen
presentation pathway. A major event in this pathway is
binding to the MHC-II molecule. The difference in the
affinity profile and the profile of natural ligands supports
the notion put forward by Nelson et al. [27], that antigen
processing continues after peptide binding to the MHC
class II molecule. First, the longer peptides bind to MHC
class II and are next trimmed by exopeptidases before
presentation.
The predictive performance of the SMM-align method is
relatively poor when compared to the performance values
obtained when predicting peptide binding for MHC class
I alleles. Here, the predictive performance in terms of the
area under the ROC curve tends to fall in the range 0.9–
0.95 depending on the allele and number of data points
available for the training [28]. There are many possible
explanations for the poor predictive performance. Most
importantly, the MHC class II binding motif is more
degenerate than that of MHC class I. For MHC class I, the
anchor positions are highly conserved, often allowing
accommodation of only a few different amino acids. As
seen from the binding motifs in Figure 2, the situation is
quite different for MHC class II. Here, even the most dom-
inant anchor positions allow for a large number of differ-
ent amino acids. Due to this high degeneracy one might
expect a general lower predictive performance. However,
there are other issues affecting the predictive performance
of the SMM-align (and most other MHC class II binding
prediction) method. The SMM-align method takes as a
fundamental assumption that the peptide:MHC binding
affinity is determined solely from the nine amino acids in
binding core motif. This is clearly a large oversimplifica-
tion since it is known that peptide flanking residues (PFR)
on both sides of the binding core may contribute to the
binding affinity and stability [29]. An example of such
influence of the peptide flanking amino acids can be
observed for the DRB1*0401 restricted peptide
WIILGLNKIVRMYSPTSI. Here, the core region
(IVRMYSPTS) as identified by both the SMM-align, and
TEPITOPE methods, is highlighted in italic. The binding
affinity for the peptide is 1.37 nM. However, also a trun-
cated version of the peptide exists in the data set,
BMC Bioinformatics 2007, 8:238 http://www.biomedcentral.com/1471-2105/8/238
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LNKIVRMYSPTSI. This peptide shares the binding core
sequence with the complete peptide, but its binding affin-
ity is 100 fold lower (177.80 nM). This example clearly
illustrates the significance of the peptide flanking amino
acids in determining the peptide binding affinity. Here,
we have incorporated the PFRs by directly encoding the
amino acids composition of the PFR's as input to the
SMM-align method, and as an ad-hoc strategy that disfa-
vors binding registers with short amino terminal PRF-
length and binding of longer peptides, and demonstrated
that these PFR modification schemes indeed lead to a sig-
nificant improvement in predictive performance.
Comparing the binding motifs identified by the NetMH-
CII and TEPITOPE method highlighted a series of funda-
mental discrepancies. For the DRB1*1302 allele, for
instance, the TEPITOPE method favors basic amino acids
at most anchor positions, whereas the NetMHCII method
identifies a preference for hydrophobic or neutral amino
acids at the anchors. The TEPITOPE and NetMHCII meth-
ods are very different in nature. The TEPITOPE binding
motif is derived using "virtual" matrices obtained by
alignment of binding pocket amino acids and experimen-
tally derived binding specificities [3]. The NetMHCII bind-
ing motif, on the other hand, is derived directly from
peptide binding data. It remains to be determined which
amino acids preference conforms to the experimental
binding motif.
Other groups have reported prediction algorithms with
very high predictive performance values also for MHC
class II binding. However, these studies have been limited
to small data sets covering a single or a few different MHC
molecules [6,8,30]. Here, we have designed a benchmark
setup allowing for large-scale validation and comparison
of MHC class II prediction algorithms. Future work based
on this type of large-scale benchmark analysis should help
identifying which methodologies are most suitable for
development of algorithms for MHC class II binding.
All peptide data for the 14 HLA-DR and three mouse H2-
IA alleles as well as the SMM-align prediction method
(NetMHCII) are made publicly available [31,32].
Methods
Data
Quantitative peptide:HLA binding data were downloaded
from the IEDB database November 2006 [13]. Only HLA
DR alleles with more than 100 unique peptides and
mouse H2-IA data with more than 75 unique peptides
were included. The final data set covers 14 HLA-DR and
three H2-IA alleles, with a total number of peptide IC50
values of 5147. This dataset is thereafter referred to as the
IEDB data set.
The SMM-align method includes a weight matrix encod-
ing the amino acids preferences identified by a Gibbs sam-
pler trained on HLA ligand data (peptides known to bind
a given HLA complex). HLA ligand data were downloaded
from the SYFPEITHI database [33]. Only peptides of nine
amino acids length or more and peptides not present in
the IEDB data set were included. A total of 360 HLA lig-
ands were included in the SYF data set.
A summary of the data is shown in Table 5
Table 5: Data included in the benchmark calculation.
HLA-DR alleles IEDB # Binders SYFPEITHI
DRB1*0101 1203 920 33
DRB1*0301 474 65 22
DRB1*0401 457 209 65
DRB1*0404 168 74 23
DRB1*0405 171 88 23
DRB1*0701 310 125 34
DRB1*0802 174 58 1
DRB1*0901 117 47 13
DRB1*1101 359 95 23
DRB1*1302 179 101 20
DRB1*1501 365 188 12
DRB3*0101 102 3 2
DRB4*0101 181 74 5
DRB5*0101 343 112 11
H2-IAb 76 43 47
H2-IAd 342 56 7
H2-IAs 126 35 19
The first column gives the allele name, the second to fourth columns the number of unique peptide data, and binders included for each allele in the 
IEDB [13] and SYFPEITHI [33] databases, respectively. Binding peptides were identified using an IC50 binding threshold of 500 nM.
BMC Bioinformatics 2007, 8:238 http://www.biomedcentral.com/1471-2105/8/238
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Designing a benchmark is quite more difficult for Class II
binding prediction compared to Class I due to the broad
length variation between the different peptides, and the
potential data redundancy this imposes. To make an eval-
uation of a prediction method, one has to define the eval-
uation set so that none of the 9 mer sequences of the
evaluation set are present in the training data. We have
designed a simple Hobohm1 [34] inspired algorithm that
aims at minimizing the overlap between training and
evaluation data. The algorithm is applied to all peptide
data for each allele. For each allele: Add each new peptide
to list of non-redundant peptide sequences, NR, if it has
no identical nonamer peptide overlap with any of the
peptides already on the NR list. Otherwise the new pep-
tide is added to the cluster defined by the first hit on the
NR list. Next all peptides in the NR list (together with their
cluster members) are split into five subsets. We are aware
that this approach does not ensure zero overlap on the 9
mer level between the different data subsets. However, the
overlap is minor and for most alleles in the order 0.5–2%
(data not shown).
Methods
Gibbs sampler weight matrices
For each allele, a weight matrix describing the binding
motif was constructed based on the relevant data in the
SYF data set and the set of binding peptides in the IEDB
training set, using the Gibbs sampler method as described
by Nielsen et al. [4]. An IC50 value of 500 nM was used
identify peptide binders from the IEDB data set.
The SMM-align method
The binding motif for all MHC class II alleles is defined in
terms of a 9 × 20 weight matrix, where 9 is the length of
the binding motif, and 20 the number of different amino
acids. The SMM-align method seeks to identify a weight
matrix that optimally reproduces the measured IC50 val-
ues for each peptide. Inspired by the work on MHC class I
binding, the IC50 affinity values in nM units are log-trans-
formed using the relation 1 - log50k(IC50 nM), before
optimizing the weights in the matrix [35]. Peptides with
affinity values greater than 50,000 nM are assigned a log-
transformed value of zero. The weight matrix is next opti-
mized so that the mean square error between predicted
and measured log50k(IC50) values is minimal.
The predicted binding affinity for a peptide sequence is
determined as the highest nonamer peptide score within
the peptide, where a nonamer peptide score is calculated
as
where wla' is the binding motif weight at position l for
amino acid a', and vala', is the sequence-encoding value for
amino acid a' for amino acid a. The peptide sequences are
presented to the SMM-align method using several
sequence-encoding schemes. The first is the conventional
sparse encoding where each amino acid is encoded as a
20-digit binary number (a single 1 and 19 zeros). The sec-
ond is the Blosum50 encoding in which the amino acids
are encoded as the Blosum50 score for replacing the
amino acid with each of the 20 amino acids [21]. Note
that since the sequence encoding for each amino acid thus
is a constant "vector", the relation for the peptide score
can be simplified to the conventional scoring scheme
For both the sparse and Blosum encoded SMM-align
matrices, the prediction scores thus converts to a simple
matrix sum.
The final prediction score for a nonomer peptide is calcu-
lated as the average of the sparse and Blosum encoded
predictions.
A Metropolis Monte Carlo (MC) procedure [26] is
invoked to search for the optimal weight matrix. Initially,
random weights are assigned to the matrix keeping the
sum at each position equal to zero. In each Monte Carlo
step, a position is selected at random, and the weight on
two amino acids are updated keeping the sum of the
weights equal to zero. The energy function guiding the
Monte Carlo search is
where si is the prediction score, mi is the measured (log-
transformed) binding affinity, N is the number of peptide
data, L is the binding motif length, A is the number of dif-
ferent amino acids, wla are the weight matrix elements,
and a term weighted by a parameter λ is introduced to
avoid over-fitting. This term penalizes high weights and
thereby forces weights that do not significantly lower the
energy function towards small values. In a small-scale
cross-validation experiment using only sparse sequence
encoding, the parameter λ was determined to have an
optimal value of 0.02.
The SMM-align method can readily be extended to
include the Gibbs sampler weight matrix, by expanding
the space of the SMM weights to include additional
weights for the L positions in the Gibbs sampler matrix. In
the Monte Carlo search, the number of weights is then
189 for a nonamer binding motif. Only non-negative val-
s v wla
a
al
la= ⋅∑∑ ’
’
’ ,
s u u v wla
l
la la
a
a
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’
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ues are allowed for the weights on the Gibbs sampler
matrix. The final weight matrix is determined as the
weighted mean of the SMM-align and Gibbs sampler
matrices, with relative weights on the Gibbs sampler
matrix determined from the Monte Carlo search.
As demonstrated earlier, the Gibbs sampler performance
can be greatly improved by restricting the number of
allowed amino acids at the P1 position in the binding
motif [4]. We adopt a similar approach, to improve the
performance of the SMM-align method for HLA-DR alle-
les. In the Monte Carlo step modifying the weights at posi-
tion P1 in the matrix, hydrophobic amino acids
(ILVMFYW) are forced to take only non-negative values,
and non-hydrophobic amino acids are forced to take only
non-positive values.
The probability of accepting a move in the Monte Carlo
search is determined by the relation
where dE is the difference in energy between the end and
start configurations, and T a scaler.
SMM-align training
Each MC search was initiated with random weights. The
scalar T was initialized to 0.01 and lowered to 0.000001
in 20 uniform steps. At each value of T, 2500 Monte Carlo
moves were performed. The acceptance of a move was
determined using Equation 2. The motif length, L, was
fixed at nine amino acids.
The configuration-space of the peptide sequences con-
tains many local minima with close to identical energy. In
order to achieve an effective sampling of these local
minima, the MC calculations were repeated 25 times with
different initial weight configurations. For each run the
final energy and weight matrix were recorded, and the top
10 scoring matrices were kept in the matrix ensemble.
In the five-fold cross-validated training the peptides were
split into five subsets as described earlier. One of the sub-
sets were left out from the SMM training and used as eval-
uation set. The remaining subsets were used to train the
weight matrix. In this manner, all peptides will in turn be
part of the evaluation set, and the predictive performance
can be estimated on all data. This approach lowers the
possible effects of over-fitting while keeping the size of
data set for evaluation maximal.
SVRMHC predictions
The SVRMHC predictions were obtained using default
parameter setting for the SVRMHC webserver [36]. The
server returns pIC50 prediction scores for each nonamer
within the query peptide, and the maximum score was
assigned as the binding pIC50 prediction value for the
query peptide.
MHCpred predictions
The MHCpred predictions were obtained using default
parameter setting for the MHCpred webserver [37]. The
server returns IC50 prediction scores for each nonamer
within the query peptide, and the minimum score was
assigned as the binding IC50 prediction value for the
query peptide.
ARB predictions
The ARB predictions were obtained using default parame-
ter setting for the ARB webserver [38].
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Additional file 1
Details of the benchmark calculation covering the 14 HLA-DR alleles. 
The predictive performance is shown in terms of the Pearson's correlation 
(upper table) and the Spearsman's rank correlation (lower table) for the 
SMM-align, Gibbs sampler [1], TEPITOPE [2], SVRMHC [3], 
MHCpred [4], and ARB methods, respectively. The SMM-PRF method 
refers to the extended SMM-align method including penalties for long pep-
tides and short amino terminal peptide flanking residues, and the NetM-
HCII method refers to the final extended SMM align method including 
direct encoding of peptide flanking residues and penalties for longer pep-
tides and short amino terminal peptide flanking residues. The first column 
gives the allele names as 1*0101 for DRB1*0101 etc The last column 
gives the number of peptide data included for each allele. For each allele, 
the performance of the SMM-align, Gibbs sampler, and NetMHCII meth-
ods was estimated using five-fold cross-validation as described in the text.
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Additional file 2
MHC-II binding affinity as a function of peptide length for three MHC-
II alleles, DRB1*0101, DRB1*0401, and DRB1*1501. In the left figure 
results for the DRB1*0101 allele are displayed, and the right figure shows 
an average over the 3 alleles. For each data set, the mean binding affinity 
for peptides of a given length is shown as a function of the peptide length. 
In black is shown the curves for the data in the AntiJen data set [5]. In 
red is shown the curves for the data in the IEDB data set [15]. The green 
curves show histograms of the length distribution of natural MHC ligands 
as downloaded from the SYFPEITHI database [31]. As suggested by 
Cheng et al., values for peptide lengths where no affinity data are availa-
ble are set to the mean binding value over the entire data set. All curves 
are smoothed using a running mean of length three. It is clear from the 
figure that the AntiJen and IEDB data sets have very distinct mean bind-
ing profiles for short peptides (length < 15 amino acids). In this regime of 
peptide lengths, the IEDB data set, in contrast to the AntiJen data set, 
seems to follow an affinity profile in agreement with the observed length 
profile for natural MHC-II ligands. For longer peptides, both the AntiJen 
and IEDB data sets follow a similar affinity profile that deviate strongly 
from the length profile of natural MHC-II ligands.
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